TABLE 1.

Cytotoxicity data for BBIQ alkaloids

BBIQ alkaloid (compound no.)	IC50 (μM) against P. falciparum straina,d:			CC50 (μM) against cancer cell line(s):		SIf
	Dd2	W2	D6	KBb or HCTc	HOEe	KB/W2	HOE/Dd2
Cycleanine (1)	17.7 ± 2.0	0.25b; 4.5c	0.07b	>33.7b; 531 (HCT)c	35.0 ± 0.1	>133	2.0
Isochondodendrine (2)	6.1 ± 1.3	0.2c	NDd	29 (HCT)c	10.5 ± 1.2	116	1.7
2′-Norcocsuline (3)	7.0 ± 1.6	0.28b	0.048b	3.8b	8.0 ± 0.2	14	1.1
5-[(Dimethylamino)methyl]cycleanine (4)	0.7 ± 0.1	ND	ND	ND	10.0 ± 0.2	ND	14.3
5-[(Propargylamino)methyl]cycleanine (5)	1.8 ± 0.2	ND	ND	ND	32.0 ± 1.6	ND	17.8
Chloroquine	0.18 ± 0.03	0.135b	0.006b	33.7b	ND	250	ND

^aIn vitro 50% inhibitory concentration (IC₅₀) values of BBIQ alkaloids (compounds 1 to 5) against P. falciparum chloroquine-resistant strains (Dd2 and W2 strains) and the chloroquine-sensitive strain (D6). IC₅₀ values are expressed as mean ± SD for n = 3 independent biological repeats.

^bIC₅₀ data against P. falciparum W2 and D6 strains and 50% cytotoxic concentration (CC₅₀) values for human oral epidermoid carcinoma (KB) cells were sourced from a previous report (16).

^cIC₅₀ data against chloroquine-resistant P. falciparum strain W2 and CC₅₀ values for HCT-116 human colon carcinoma cells were sourced from a previous report (18).

^dND, not determined.

^eCC₅₀ data for human ovarian epithelial (HOE) cells. Data in this column for compounds 1 to 5 were sourced from our previous reports (13, 15).

^fThis selectivity index (SI) was calculated as CC₅₀ /IC₅₀ against P. falciparum.